- Investing.com
Metrics to compare | AIMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAIMDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.9x | −0.9x | 13.1x | |
PEG Ratio | −0.02 | −0.09 | 0.01 | |
Price/Book | 1.7x | 2.6x | 2.4x | |
Price / LTM Sales | 101.2x | 23.3x | 2.5x | |
Upside (Analyst Target) | - | 101.6% | 21.8% | |
Fair Value Upside | Unlock | 12.4% | 0.7% | Unlock |
Ainos, Inc., a dual-platform company, focusing artificial intelligence–based smelltech technologies and immune therapeutics. It offers AI Nose, an AI-based electronic olfaction system, which uses a smell language model to digitize scent into Smell IDs and turning into machine-readable data. The company provides its platforms for semiconductor manufacturing, robotics, and smart manufacturing industries; as well as senior care and women’s health sectors. In addition, it develops VELDONA, a low-dose oral interferon platform for human and animal health applications, targeting rare, autoimmune, and infectious diseases. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in Houston, Texas. Ainos, Inc. is a subsidiary of Taiwan Carbon Nano Technology Corporation.